Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic mecapegfilgrastim after postoperative radiotherapy in solid tumors
ChiCTR2100049796Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Central Hospital
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in Nonhematologic neoplasms, sponsored by Zhengzhou Central Hospital. Primary endpoint: Incidence of grade III/IV neutropenia during the radiotherapy cycle after mecapegfilgrastim administration. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100049796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049796.